Amisulpride

Generic Name
Amisulpride
Brand Names
Barhemsys
Drug Type
Small Molecule
Chemical Formula
C17H27N3O4S
CAS Number
71675-85-9
Unique Ingredient Identifier
8110R61I4U
Background

Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride ...

Indication

Intravenous amisulpride is indicated in adults for the prevention of postoperative nausea and vomiting, either alone or in combination with an antiemetic of a different class. It is also indicated for the treatment of postoperative nausea and vomiting in patients who have received anti-emetic prophylaxis with an agent of a different class or have not receive...

Associated Conditions
Acute Schizophrenia, Chronic Schizophrenia, Negative Symptoms, Post Operative Nausea and Vomiting (PONV)
Associated Therapies
-
Clinical Trials
Related News

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

First Posted Date
2014-12-04
Last Posted Date
2018-10-11
Lead Sponsor
Technical University of Munich
Target Recruit Count
21
Registration Number
NCT02307396
Locations
🇩🇪

Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar, Munich, Bavaria, Germany

Association of Amisulpride Response in Schizophrenia With Brain Image

First Posted Date
2014-03-26
Last Posted Date
2014-03-26
Lead Sponsor
CHA University
Target Recruit Count
20
Registration Number
NCT02095938

Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study

First Posted Date
2014-01-31
Last Posted Date
2018-03-08
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
74
Registration Number
NCT02051387
Locations
🇩🇪

Dept. of Pharmacology, University of Cologne, Cologne, NRW, Germany

🇩🇪

Central Institute of Mental Health, Mannheim, BW, Germany

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

First Posted Date
2013-10-30
Last Posted Date
2024-06-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
105
Registration Number
NCT01972711
Locations
🇬🇧

University of Manchester, Neuroscience and Psychiatry Unit, Manchester, United Kingdom

🇬🇧

Department of Psychiatry, University of Oxford, Warneford Hospital, Headington, Oxford, United Kingdom

Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: AMISULPRIDE
First Posted Date
2013-02-20
Last Posted Date
2015-01-22
Lead Sponsor
Sanofi
Target Recruit Count
316
Registration Number
NCT01795183
Locations
🇨🇳

Sanofi-Aventis Administrative Office, Beijing, China

An Investigation of Early Life Stress and Depression

First Posted Date
2012-10-05
Last Posted Date
2018-05-18
Lead Sponsor
Mclean Hospital
Target Recruit Count
153
Registration Number
NCT01701258
Locations
🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

First Posted Date
2012-05-31
Last Posted Date
2019-04-16
Lead Sponsor
Heinrich-Heine University, Duesseldorf
Target Recruit Count
328
Registration Number
NCT01609153
Locations
🇩🇪

LWL-Klinik Dortmund, Dortmund, Germany

🇩🇪

Zentrum für Seelische Gesundheit Kreiskliniken Darmstadt-Dieburg Standort: Groß-Umstadt, Groß-Umstadt, Germany

🇩🇪

Universitätsmedizin Mainz Klinik für Psychiatrie und Psychotherapie, Mainz, Germany

and more 18 locations

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

First Posted Date
2012-03-15
Last Posted Date
2016-10-26
Lead Sponsor
Birte Glenthoj
Target Recruit Count
56
Registration Number
NCT01555814
Locations
🇩🇰

Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark, Glostrup, Denmark

An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)

First Posted Date
2011-12-23
Last Posted Date
2022-02-04
Lead Sponsor
Organon and Co
Target Recruit Count
42
Registration Number
NCT01498770
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy